Order,Study,Date,Doses,Ages,Effectiveness,ve_hosp_minus_error,ve_hosp_plus_error
1,"Arbel et al, Apr-22",22-Apr,4 vs 3 Doses (>60yo) Adjusted,60-100,0.64,0.07,0.05
2,"Arbel et al, Jan-23",23-Jan,Bivalent vs 0+ (>65yo) SSRN Adjusted,>65 years (SSRN),0.81,0.11,0.24
3,"Arbel et al, Apr-23",23-Apr,Bivalent vs 0+ (>65yo) Lancet Adjusted,>65 years (Lancet),0.78,0.18,0.03
4,"Barda et al, Dec-21",21-Dec,3 vs 2 Doses (>12yo) Matched,">12, median age 52",0.93,0.05,0.04
5,"Dagan et al., Apr-21",21-Apr,2 vs 0 Doses (>16yo) Matched,>16 years,0.87,0.32,0.13
6,"Magen et al, Apr 22",22-Apr,4 vs 3 Doses (>60yo) Matched,>60,0.68,0.09,0.06